Insights into the effects of complement factor H on the assembly and decay of the alternative pathway C3 proconvertase and C3 convertase

Journal of Biological Chemistry

Volumn 291, Issue 15, 2016, Pages 8214-8230

  Bettoni, Serena ^a   Bresin, Elena ^a   Remuzzi, Giuseppe ^a,b,c   Noris, Marina ^a   Donadelli, Roberta ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b Azienda Ospedaliera Papa Giovanni XXIII   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BINS; DISSOCIATION;

CELL-BASED; INHIBITORY EFFECT; MICROPLATES; USER FRIENDLY;

DECAY (ORGANIC);

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3BB; COMPLEMENT FACTOR H; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; IMMUNOGLOBULIN G; MAGNESIUM ION; NICKEL; POLYANION; SIALIC ACID; UNCLASSIFIED DRUG; ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C3B; MANGANESE; PROPERDIN;

ARTICLE; BINDING AFFINITY; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DENSITOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN INTERACTION; PROTEIN SECRETION; WESTERN BLOTTING; IMMUNOLOGY;

COMPLEMENT C3; COMPLEMENT C3 CONVERTASE, ALTERNATIVE PATHWAY; COMPLEMENT C3-C5 CONVERTASES; COMPLEMENT C3B; COMPLEMENT FACTOR B; COMPLEMENT FACTOR H; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MANGANESE; PROPERDIN;

EID: 84964626186     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M115.693119     Document Type: Article

References (61)

1. Walport, M. J. (2001) Complement. First of two parts. N. Engl. J. Med. 344, 1058-1066
2. Walport, M. J. (2001) Complement. Second of two parts. N. Engl. J. Med. 344, 1140-1144
3. Ricklin, D., Hajishengallis, G., Yang, K., and Lambris, J. D. (2010) Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 11, 785-797
4. Noris, M., and Remuzzi, G. (2009) Atypical hemolytic-uremic syndrome. N. Engl. J. Med. 361, 1676-1687
5. Noris, M., and Remuzzi, G. (2013) Overview of complement activation and regulation. Semin. Nephrol. 33, 479-492
6. Rodríguez de Córdoba, S., Harris, C. L., Morgan, B. P., and Llorca, O. (2011) Lessons from functional and structural analyses of disease-associated genetic variants in the complement alternative pathway. Biochim. Biophys. Acta 1812, 12-22
7. Bomback, A. S., and Appel, G. B. (2012) Pathogenesis of the C3 glomerulopathies and reclassification of MPGN. Nat. Rev. Nephrol. 8, 634-642
8. Sethi, S., Fervenza, F. C., Zhang, Y., Zand, L., Vrana, J. A., Nasr, S. H., Theis, J. D., Dogan, A., and Smith, R. J. (2012) C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int. 82, 465-473
9. McHarg, S., Clark, S. J., Day, A. J., and Bishop, P. N. (2015) Age-related macular degeneration and the role of the complement system. Mol. Immunol. 67, 43-50
10. Gruppo, R. A., and Rother, R. P. (2009) Eculizumab for congenital atypical hemolytic-uremic syndrome. N. Engl. J. Med. 360, 544-546
11. Legendre, C. M., Licht, C., Muus, P., Greenbaum, L. A., Babu, S., Bedrosian, C., Bingham, C., Cohen, D. J., Delmas, Y., Douglas, K., Eitner, F., Feldkamp, T., Fouque, D., Furman, R. R., Gaber, O., et al. (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N. Engl. J. Med. 368, 2169-2181
12. Zuber, J., Fakhouri, F., Roumenina, L. T., Loirat, C., Frémeaux-Bacchi, V., French Study Group for aHUS/C3G. (2012) Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat. Rev. Nephrol. 8, 643-657
13. Daina, E., Noris, M., and Remuzzi, G. (2012) Eculizumab in a patient with dense-deposit disease. N. Engl. J. Med. 366, 1161-1163
14. Vivarelli, M., and Emma, F. (2014) Treatment of C3 glomerulopathy with complement blockers. Semin. Thromb. Hemost. 40, 472-477
15. Nester, C. M., and Smith, R. J. (2013) Treatment options for C3 glomerulopathy. Curr. Opin. Nephrol. Hypertens. 22, 231-237
16. Leslie, M. (2012) Immunology. The new view of complement. Science 337, 1034-1037
17. Fearon, D. T., and Austen, K. F. (1975) Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. J. Exp. Med. 142, 856-863
18. Hourcade, D. E. (2006) The role of properdin in the assembly of the alternative pathway C3 convertases of complement. J. Biol. Chem. 281, 2128-2132
19. Zipfel, P. F., and Skerka, C. (2009) Complement regulators and inhibitory proteins. Nat. Rev. Immunol. 9, 729-740
20. Pangburn, M. K., Schreiber, R. D., and Müller-Eberhard, H. J. (1977) Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein β1H for cleavage of C3b and C4b in solution. J. Exp. Med. 146, 257-270
21. Weiler, J. M., Daha, M. R., Austen, K. F., and Fearon, D. T. (1976) Control of the amplification convertase of complement by the plasma protein β1H. Proc. Natl. Acad. Sci. U.S.A. 73, 3268-3272
22. Whaley, K., and Ruddy, S. (1976) Modulation of the alternative complement pathways by β1H globulin. J. Exp. Med. 144, 1147-1163
23. Conrad, D. H., Carlo, J. R., and Ruddy, S. (1978) Interaction of β1H globulin with cell-bound C3b: quantitative analysis of binding and influence of alternative pathway components on binding. J. Exp. Med. 147, 1792-1805
24. Pangburn, M. K., and Müller-Eberhard, H. J. (1978) Complement C3 convertase: cell surface restriction of β1H control and generation of restriction on neuraminidase-treated cells. Proc. Natl. Acad. Sci. U.S.A. 75, 2416-2420
25. Kazatchkine, M. D., Fearon, D. T., and Austen, K. F. (1979) Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and β1H for cell-bound C3b. J. Immunol. 122, 75-81
26. Tortajada, A., Montes, T., Martínez-Barricarte, R., Morgan, B. P., Harris, C. L., and de Córdoba, S. R. (2009) The disease-protective complement factor H allotypic variant Ile62 shows increased binding affinity for C3b and enhanced cofactor activity. Hum. Mol. Genet. 18, 3452-3461
27. Hourcade, D. E., Mitchell, L. M., and Medof, M. E. (1999) Decay acceleration of the complement alternative pathway C3 convertase. Immunopharmacology 42, 167-173
28. Makou, E., Herbert, A. P., and Barlow, P. N. (2013) Functional anatomy of complement factor H. Biochemistry 52, 3949-3962
29. Schmidt, C. Q., Herbert, A. P., Hocking, H. G., Uhrín, D., and Barlow, P. N. (2008) Translational mini-review series on complement factor H: structural and functional correlations for factor H. Clin. Exp. Immunol 151, 14-24
30. Rodríguez de Córdoba, S., Esparza-Gordillo, J., Goicoechea de Jorge, E., Lopez-Trascasa, M., and Sánchez-Corral, P. (2004) The human complement factor H: functional roles, genetic variations and disease associations. Mol. Immunol. 41, 355-367
31. Hourcade, D. E., Wagner, L. M., and Oglesby, T. J. (1995) Analysis of the short consensus repeats of human complement factor B by site-directed mutagenesis. J. Biol. Chem. 270, 19716-19722
32. Hourcade, D. E., Mitchell, L., Kuttner-Kondo, L. A., Atkinson, J. P., and Medof, M. E. (2002) Decay-accelerating factor (DAF), complement receptor 1 (CR1), and factor H dissociate the complement AP C3 convertase (C3bBb) via sites on the type A domain of Bb. J. Biol. Chem. 277, 1107-1112
33. Hourcade, D. E., and Mitchell, L. M. (2011) Access to the complement factor B scissile bond is facilitated by association of factor B with C3b protein. J. Biol. Chem. 286, 35725-35732
34. Fishelson, Z., and Müller-Eberhard, H. J. (1982) C3 convertase of human complement: enhanced formation and stability of the enzyme generated with nickel instead of magnesium. J. Immunol. 129, 2603-2607
35. Kouser, L., Abdul-Aziz, M., Nayak, A., Stover, C. M., Sim, R. B., and Kishore, U. (2013) Properdin and factor H: opposing players on the alternative complement pathway "see-saw". Front. Immunol. 4, 93
36. Frémeaux-Bacchi, V., Weiss, L., Brun, P., and Kazatchkine, M. D. (1994) Selective disappearance of C3NeF IgG autoantibody in the plasma of a patient with membranoproliferative glomerulonephritis following renal transplantation. Nephrol. Dial. Transplant. 9, 811-814
37. Torreira, E., Tortajada, A., Montes, T., Rodríguez de Córdoba, S., and Llorca, O. (2009) 3D structure of the C3bB complex provides insights into the activation and regulation of the complement alternative pathway convertase. Proc. Natl. Acad. Sci. U.S.A. 106, 882-887
38. Harris, C. L., Abbott, R. J., Smith, R. A., Morgan, B. P., and Lea, S. M. (2005) Molecular dissection of interactions between components of the alternative pathway of complement and decay accelerating factor (CD55). J. Biol. Chem. 280, 2569-2578
39. Morgan, H. P., Schmidt, C. Q., Guariento, M., Blaum, B. S., Gillespie, D., Herbert, A. P., Kavanagh, D., Mertens, H. D., Svergun, D. I., Johansson, C. M., Uhrín, D., Barlow, P. N., and Hannan, J. P. (2011) Structural basis for engagement by complement factorHof C3b on a self-surface. Nat. Struct. Mol. Biol. 18, 463-470
40. Alcorlo, M., Tortajada, A., Rodríguez de Córdoba, S., and Llorca, O. (2013) Structural basis for the stabilization of the complement alternative pathway C3 convertase by properdin. Proc. Natl. Acad. Sci. U.S.A. 110, 13504-13509
41. Jelezarova, E., Schlumberger, M., Sadallah, S., Späth, P. J., Schifferli, J. A., and Lutz, H. U. (2001) A C3 convertase assay for nephritic factor functional activity. J. Immunol. Methods 251, 45-52
42. Paixão-Cavalcante, D., López-Trascasa, M., Skattum, L., Giclas, P. C., Goodship, T. H., de Córdoba, S. R., Truedsson, L., Morgan, B. P., and Harris, C. L. (2012) Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation. Kidney Int. 82, 1084-1092
43. Lavigne, K. M., Rapin, L. A., Metzak, P. D., Whitman, J. C., Jung, K., Dohen, M., Loevenbruck, H., and Woodward, T. S. (2015) Left-dominant temporal-frontal hypercoupling in schizophrenia patients with hallucinations during speech perception. Schizophr. Bull. 41, 259-267
44. Blaum, B. S., Hannan, J. P., Herbert, A. P., Kavanagh, D., Uhrín, D., and Stehle, T. (2015) Structural basis for sialic acid-mediated self-recognition by complement factor H. Nat. Chem. Biol. 11, 77-82
45. Nilsson, U. R., Storm, K. E., Elwing, H., and Nilsson, B. (1993) Conformational epitopes of C3 reflecting its mode of binding to an artificial polymer surface. Mol. Immunol. 30, 211-219
46. Roumenina, L. T., Loirat, C., Dragon-Durey, M. A., Halbwachs-Mecarelli, L., Sautes-Fridman, C., and Fremeaux-Bacchi, V. (2011) Alternative complement pathway assessment in patients with atypical HUS. J. Immunol. Methods 365, 8-26
47. Mollnes, T. E., Jokiranta, T. S., Truedsson, L., Nilsson, B., Rodriguez de Cordoba, S., and Kirschfink, M. (2007) Complement analysis in the 21st century. Mol. Immunol. 44, 3838-3849
48. Jokiranta, T. S., Westin, J., Nilsson, U. R., Nilsson, B., Hellwage, J., Löfås, S., Gordon, D. L., Ekdahl, K. N., and Meri, S. (2001) Complement C3b interactions studied with surface plasmon resonance technique. Int. Immunopharmacol. 1, 495-506
49. Goicoechea de Jorge, E., Harris, C. L., Esparza-Gordillo, J., Carreras, L., Arranz, E. A., Garrido, C. A., López-Trascasa, M., Sánchez-Corral, P., Morgan, B. P., and Rodríguez de Córdoba, S. (2007) Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc. Natl. Acad. Sci. U.S.A. 104, 240-245
50. Hui, K. M., Magnadóttir, B., Schifferli, J. A., and Inal, J. M. (2006) CRIT peptide interacts with factor B and interferes with alternative pathway activation. Biochem. Biophys. Res. Commun. 344, 308-314
51. Janssen, B. J., Huizinga, E. G., Raaijmakers, H. C., Roos, A., Daha, M. R., Nilsson-Ekdahl, K., Nilsson, B., and Gros, P. (2005) Structures of comple-ment component C3 provide insights into the function and evolution of immunity. Nature 437, 505-511
52. Torreira, E., Tortajada, A., Montes, T., Rodríguez de Córdoba, S., and Llorca, O. (2009) Coexistence of closed and open conformations of complement factor B in the alternative pathway C3bB(Mg2+) proconvertase. J. Immunol. 183, 7347-7351
53. Milder, F. J., Gomes, L., Schouten, A., Janssen, B. J., Huizinga, E. G., Romijn, R. A., Hemrika, W., Roos, A., Daha, M. R., and Gros, P. (2007) Factor B structure provides insights into activation of the central protease of the complement system. Nat. Struct. Mol. Biol. 14, 224-228
54. Forneris, F., Ricklin, D., Wu, J., Tzekou, A., Wallace, R. S., Lambris, J. D., and Gros, P. (2010) Structures of C3b in complex with factors B andDgive insight into complement convertase formation. Science 330, 1816-1820
55. Servais, A., Noël, L. H., Roumenina, L. T., Le Quintrec, M., Ngo, S., Dragon-Durey, M. A., Macher, M. A., Zuber, J., Karras, A., Provot, F., Moulin, B., Grünfeld, J. P., Niaudet, P., Lesavre, P., and Frémeaux-Bacchi, V. (2012) Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int. 82, 454-464
56. Wu, J., Wu, Y. Q., Ricklin, D., Janssen, B. J., Lambris, J. D., and Gros, P. (2009) Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. Nat. Immunol. 10, 728-733
57. Pangburn, M. K. (2000) Host recognition and target differentiation by factor H, a regulator of the alternative pathway of complement. Immunopharmacology 49, 149-157
58. Jokiranta, T. S., Cheng, Z. Z., Seeberger, H., Jòzsi, M., Heinen, S., Noris, M., Remuzzi, G., Ormsby, R., Gordon, D. L., Meri, S., Hellwage, J., and Zipfel, P. F. (2005) Binding of complement factor H to endothelial cells is mediated by the carboxy-terminal glycosaminoglycan binding site. Am. J. Pathol. 167, 1173-1181
59. Lehtinen, M. J., Rops, A. L., Isenman, D. E., van der Vlag, J., and Jokiranta, T. S. (2009) Mutations of factorHimpair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome. J. Biol. Chem. 284, 15650-15658
60. Janssen, B. J., Gomes, L., Koning, R. I., Svergun, D. I., Koster, A. J., Fritzinger, D. C., Vogel, C. W., and Gros, P. (2009) Insights into complement convertase formation based on the structure of the factor B-cobra venom factor complex. EMBO J. 28, 2469-2478
61. Janssen, B. J., Christodoulidou, A., McCarthy, A., Lambris, J. D., and Gros, P. (2006) Structure of C3b reveals conformational changes that underlie complement activity. Nature 444, 213-216